Regnum Corp. (RGMP) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRegnum Corp. (RGMP) trades at $0.0001. Regnum Corp. is a biotechnology company focused on developing and commercializing therapeutics for rare and infectious diseases. Sector: Communication services.
Price as of · Last analyzed: Mar 15, 2026Analyst Coverage for RGMP: RGMP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Regnum Corp. (RGMP) Media & Communications Profile
Regnum Corp. is a biotechnology firm specializing in the development of therapeutics for rare and infectious diseases, with a primary focus on Leronlimab (PRO 140), a CCR5 antagonist for HIV treatment. The company operates as a subsidiary of Phoenixus AG, navigating the competitive biotechnology landscape.
What Is the Investment Thesis for RGMP?
Regnum Corp. presents a high-risk, high-reward investment profile, primarily centered on the potential of Leronlimab. The company's success hinges on securing regulatory approvals and demonstrating clinical efficacy across various indications. Key value drivers include successful completion of clinical trials, strategic partnerships, and market acceptance of Leronlimab. Investors should closely monitor clinical trial results, regulatory filings, and competitive developments within the HIV and infectious disease therapeutic landscape. The company's small size and OTC listing contribute to heightened volatility and liquidity risks. As of 2026-03-15, the company's market capitalization is $0.00B, reflecting the speculative nature of the investment.
Based on FMP financials and quantitative analysis
RGMP Key Highlights
Regnum Corp. focuses on developing Leronlimab (PRO 140), a monoclonal antibody CCR5 antagonist, targeting HIV.
- The company operates as a subsidiary of Phoenixus AG.
- Regnum Corp. is based in New York City.
- The company has a market capitalization of $0.00B as of 2026-03-15.
- The company has a P/E ratio of -0.00, reflecting its current lack of profitability.
Who Are RGMP's Competitors?
RGMP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ZNB Zeta Network Group | $1.54 | +45.28% | — | |
| TDIC Dreamland Limited Class A Ordinary Shares | $2.14 | -3.17% | — | |
| NIPG NIP Group Inc. | $11.05 | -0.90% | $10.4M | — |
| DLPN Dolphin Entertainment, Inc. | $1.03 | -2.83% | $13.4M | — |
| LVO LiveOne, Inc. | $2.63 | +1.94% | $28.9M | — |
| TOON Kartoon Studios Inc. | $0.56 | -1.63% | $33.2M | 32 5-pillar |
| GAIA Gaia, Inc. | $1.39 | 0.00% | $34.8M | — |
| CNVS Cineverse Corp. | $1.91 | -2.31% | $44.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RGMP's Key Strengths?
Novel therapeutic approach with Leronlimab.
- Potential for expanded indications beyond HIV.
- Focus on unmet medical needs in infectious diseases.
- Subsidiary of Phoenixus AG provides financial backing.
What Are RGMP's Weaknesses?
Limited financial resources.
- Dependence on a single product candidate (Leronlimab).
- Small team size (1 employee).
- OTC listing indicates higher risk.
What Are the Key Risks for RGMP?
Financial-distress signal — its Altman Z-Score of -12.34 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or negative results.
- Regulatory delays or rejections.
- Competition from established HIV therapies.
- Limited financial resources and dependence on a single product candidate.
- OTC listing indicates higher risk and lower liquidity.
What Threats Does RGMP Face?
- Competition from established HIV therapies.
- Regulatory hurdles and clinical trial failures.
- Patent expirations and generic competition.
- Economic downturn and reduced healthcare spending.
What Are RGMP's Competitive Advantages?
- Patented therapeutic (Leronlimab) provides exclusivity.
- Specialized expertise in monoclonal antibody development.
- Established relationships with regulatory agencies.
- Potential for expanded indications beyond HIV.
What Does RGMP Do?
Regnum Corp., a subsidiary of Phoenixus AG, is a biotechnology company dedicated to the development and commercialization of innovative therapeutics targeting rare and infectious diseases. The company's primary focus is on Leronlimab (PRO 140), a monoclonal antibody designed to block the CCR5 receptor, thereby preventing HIV from entering human cells. Founded with the goal of addressing unmet medical needs in the field of infectious diseases, Regnum Corp. has concentrated its efforts on advancing Leronlimab through clinical trials and seeking regulatory approvals. Based in New York City, Regnum Corp. operates within the highly competitive biotechnology sector, striving to bring novel treatments to market. Leronlimab represents the core of the company's pipeline, with potential applications beyond HIV, including research into its efficacy in other diseases. The company's strategy involves rigorous scientific research, clinical development, and strategic partnerships to maximize the potential of its lead therapeutic. Regnum Corp. aims to establish itself as a key player in the development of therapies for challenging and underserved medical conditions.
What Products and Services Does RGMP Offer?
- Develops therapeutics for rare and infectious diseases.
- Commercializes therapeutics for rare and infectious diseases.
- Focuses on Leronlimab (PRO 140), a monoclonal antibody.
- Leronlimab is a CCR5 antagonist designed to prevent HIV from entering human cells.
- Conducts clinical trials to evaluate the safety and efficacy of Leronlimab.
- Seeks regulatory approvals for Leronlimab in various markets.
How Does RGMP Make Money?
- Develops and patents novel therapeutics.
- Conducts clinical trials to demonstrate efficacy and safety.
- Seeks regulatory approval from agencies like the FDA.
- Commercializes approved therapeutics through sales and marketing efforts.
What Industry Does RGMP Operate In?
Regnum Corp. operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for HIV therapeutics is well-established but continues to evolve with the emergence of new drug classes and treatment strategies. Companies like Regnum Corp. face the challenge of differentiating their products and demonstrating superior efficacy and safety compared to existing therapies. The biotechnology industry is driven by innovation, with companies constantly seeking to develop novel treatments for unmet medical needs. Regnum Corp.'s focus on Leronlimab positions it within the competitive landscape of HIV and infectious disease therapeutics.
Who Are RGMP's Key Customers?
- Patients with HIV.
- Healthcare providers who treat patients with HIV.
- Hospitals and clinics that administer HIV therapies.
- Pharmaceutical distributors and wholesalers.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Regnum Corp. operates in the Communication Services sector. It is headquartered in New York City, US. The company is led by CEO Robert J. Stubblefield. RGMP has traded publicly since 2019.
Key Financial Metrics
Return on equity for Regnum Corp. stands at 101.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -90.3%, showing how much profit it generates from its asset base. A current ratio of 0.43 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Regnum Corp.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.34 places it in the distress zone, a signal of elevated financial risk.
RGMP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
RGMP Latest News
No recent news available for RGMP.
RGMP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RGMP.
Price Targets
Wall Street price target analysis for RGMP.
RGMP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RGMP; grades run from A+ (80-100) to F (below 30).
Leadership: Robert J. Stubblefield
Managing Employee
Robert J. Stubblefield serves as the managing employee of Regnum Corp. As the leader of a small team, Stubblefield is responsible for overseeing all aspects of the company's operations, including research and development, clinical trials, and regulatory affairs. His experience in the biotechnology industry is crucial for guiding Regnum Corp. through the complex and competitive landscape of drug development.
Track Record: Due to the limited information available, it is difficult to assess Robert J. Stubblefield's specific achievements and strategic decisions at Regnum Corp. However, as the managing employee, he is responsible for driving the company's efforts to advance Leronlimab through clinical trials and seek regulatory approvals. His leadership will be critical in determining the success of Regnum Corp. and its ability to bring innovative therapies to market.
RGMP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Regnum Corp. may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosures.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Understand the company's business model and competitive landscape.
- Evaluate the potential risks and rewards of investing in the company.
- Consult with a qualified financial advisor.
- Research the company's history and any past legal or regulatory issues.
- Subsidiary of Phoenixus AG.
- Focus on developing therapeutics for unmet medical needs.
- Development of Leronlimab (PRO 140).
- Company is based in New York City.
RGMP Communication Services Stock FAQ
What do analysts say about RGMP stock?
As of 2026-03-15, formal analyst coverage of RGMP is limited, likely due to its OTC listing and small market capitalization.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing indicates higher risk and lower liquidity.
- Small team size and dependence on a single product candidate.